This website uses cookies to enhance your browsing experience, improve site performance, and gather analytics. By selecting 'Accept,' you consent to these cookies as described in our Privacy Policy.

COmparison of Clarus and Optos Ultrawide Field Imaging Systems for Geographic Atrophy

Sponsored by University of Wisconsin, Madison

About this trial

Last updated 2 years ago

Study ID

2023-0958

Status

Recruiting

Type

Interventional

Phase

N/A

Placebo

No

Accepting

18-75 Years
50+ Years
All
All

Not accepting

Not accepting
Healthy Volunteers

Trial Timing

Ended a year ago

What is this trial about?

The goal of this clinical trial is to compare measurements of geographic atrophy (GA) area between several types of imaging, in order to assess accuracy. The main question to answer is which imaging device provides measurements that are most similar to the standard of care device. Participants will be patients of a retina doctor at University Station Eye Clinic with geographic atrophy, and can expect to be in the study for 60-75 minutes.

What are the participation requirements?

Yes

Inclusion Criteria

- 50 years or older and may be either male or female and may be of any race

- Established diagnosis of GA due to AMD

- GA characteristics: GA area of between 1.25 mm² and 23 mm², with seventy percent of eyes having GA area ranging from 2.5 mm² to 17.5 mm². GA may be unifocal or multifocal. GA may be subfoveal or extrafoveal, with twenty-five percent of eyes having subfoveal GA. The presence of concurrent peripapillary atrophy will not exclude subjects from participation

- Willing to participate as evidenced by signing the written informed consent

No

Exclusion Criteria

- Unable to tolerate opthalmic imaging

- Presence of neovascular AMD on OCT as confirmed by an ophthalmologist

- Presence of significant media opacity preventing adequate retinal imaging

- Presence of concurrent retinal disease which may confound assessment

Locations

Location

Status

Recruiting